Can a simple shot replace monthly IV for kidney patients?
NCT ID NCT04955366
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study looks at whether kidney transplant patients can safely switch from a monthly IV drug called belatacept to a self-injected drug called abatacept without harming their kidney function. About 87 adults who are at least 2 years post-transplant and on belatacept will be randomly assigned to either stay on belatacept or switch to abatacept. The main goal is to compare kidney function over 12 months between the two groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital (EUH)
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.